Prostate cancer is the most commonly diagnosed cancer in Australia according to Australian Institute of Health and Welfare (AIHW). Anyone with a prostate is at risk of this disease.

At Medlogical Innovations, our mission is to drive better outcomes in prostate cancer management with precision-engineered and purpose-designed technology for focal therapy.

NIH National Cancer Institute - Prostate Cancer — Cancer Stat Facts.
https://seer.cancer.gov/statfacts/html/prost.html

Australian men have a 1 in 5 risk of being diagnosed with prostate cancer by the time they reach 85 years old

INTRODUCING
FOCAL THERAPY

Focal or targeted therapy aims to treat a specific lesion or area within the prostate gland, while preserving healthy prostate. 

 

ProFocal uses a laser energy source intended to deliver focal hyperthermia in adult men with localised, non-metastatic, intermediate grade prostate disease.

 

ProFocal is not included on the TGA ARTG in Australia. Available in select international geographies.

CLINICAL STUDY HIGHLIGHTS

Initial Clinical Trial of Focal Laser Ablation Utilizing ProFocal-Rx For Localized Prostate Cancer. Kam, J. et al. 2023. Journal of Urology Vol.209, Issue Supplement 4, e859

Results from the ProFocal pivotal study are published in the BJU International medical journal. It is an Open Access article and can be accessed at Focal therapy using a novel cooled laser device for prostate cancer: early trial results – Kam – BJU International – Wiley Online Library

Scroll to Top